Ultimovacs ASA – Annual General Meeting held on April 18, 2024
Oslo, April 18, 2023: Ultimovacs ASA held its annual general meeting today April 18, 2024. All the matters on the agenda were approved.
The following board members were re-elected for a period of one year, and the Board of Directors will consist of the following persons:
- Jónas Einarsson, Chair of the Board
- Henrik Schüssler, board member
- Kari Grønås, board member
- Ketil Fjerdingen, deputy board member
The Nomination Committee will consist of the following persons until the Annual General Meeting in 2025:
- Ole Kristian Hjelstuen, Chair of the committee
- Hans Peter Bøhn, committee member
The minutes from the meeting are enclosed and available at the company’s website.
For further information, please see www.ultimovacs.com or contact:
Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA
Email: je@radforsk.no
Phone: +47 480 96 355
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com
Phone: +47 906 86815
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Suspension af udvalgte afdelinger den 6. maj 20241.5.2024 14:52:03 CEST | pressemeddelelse
Det skal oplyses, at nedenstående afdelinger vil være suspenderet for handel mandag den 6. maj 2024. ISINOrder book codeAfdelingsnavn før ændringAfdelingsnavn efter ændringDK0060254043SPVINONye obligationsmarkederINDEX Emerging Market Bonds LokalvalutaDK0060254126SPVINOAKKKLANye obligationsmarkeder Akk. – KL AINDEX Emerging Market Bonds Lokalvaluta Akk. – KL A Suspension af disse afdelinger kommer i forlængelse af tidligere fondbørsmeddelelse den 19. april 2024 vedrørende ædnringer i ovenstående fonde. Det vurderes, at det ikke er hensigtmæssigt at stille priser i markedet på ovenstående afdelinger den 6. maj 2024, hvorfor suspensionen forlænges til og med denne dag. Eventuel henvendelse vedrørende denne meddelelse kan rettes til npa.pm@nykredit.dk, cc jna@nykredit.dk Med venlig hilsen Morten Skipper Direktør, ID-Sparinvest, Filial af Sparinvest S.A., Luxembourg
Alternus Clean Energy set to Acquire Over 80 MWp of Operating Solar PV across eight states in the U.S.1.5.2024 14:40:00 CEST | Press release
On completion will be immediately EBITDA accretive FORT MILL, S.C., May 01, 2024 (GLOBE NEWSWIRE) -- Alternus Clean Energy, Inc. (NASDAQ: ALCE) (“Alternus” or the “Company”), a leading utility-scale transatlantic, clean energy independent power producer (IPP) today announced the signing of definitive agreements with a U.S. based fund to acquire over 80 MWp of operating portfolio spanning across the U.S. The Portfolio consists of 33 projects, distributed across eight states, showcasing a geographical diversification within the U.S. The portfolio has significant long-term agreements (average remaining term of over 12 years) with 16 different counterparties. Notably, approximately 20% of these fall within the AAA and AA rating categories, such as Duke Energy, enhancing the financial stability and predictability of revenue streams. The Portfolio is expected to generate an average of $6.7 million of revenue and $5.1 million (before improvements) of operating income annually and represents a
Novo Nordisk A/S - share repurchase programme1.5.2024 14:30:46 CEST | Press release
Bagsværd, Denmark, 1 May 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 6 February 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.1 billion in the period from 6 February 2024 to 30 April 2024. The programme is now concluded. Since the announcement 22 April 2024, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKKAccumulated, last announcement2,133,5001,846,074,35122 April 202442,000859.5736,101,80523 April 202442,000881.9837,043,21124 April 202441,000885.2536,295,24925 April 202441,00
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics1.5.2024 14:01:00 CEST | Press release
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO. Rachelle Jacques will step down as Akari’s Chief Executive Officer effective today. Melissa Bradford-Klug will step down as Akari’s Chief Operating Officer effective today. In connection with Ms. Jacques’ departure, Akari’s board of directors (the “Board”) has appointed Dr. Patel as Interim Chief Executive Officer. Dr. Patel has served as a member of the Board since December 2023. “I am honored to be appointed interim CEO by the Akari Board of Directors. My immediate goals are timely completion of the previously announced merger between Akari Therapeutics and Peak Bio, implementation of the portfolio prioritization agreed upon by the boards of both companies whil
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity1.5.2024 14:00:00 CEST | Press release
Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic diseaseAkari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak’s ADC (antibody drug conjugate) platform technology and Akari’s PAS-nomacopan Geographic Atrophy (GA) program. Peak’s ADC platform technology is a proprietary technology using antibody plus linker plus Peak Bio toxin with immune modulation and includes a novel pre-clinical ADC candidate targeting TROP-2. Akari’s PAS-nomacopan is a bispecific complement and leukotriene B4 inhibitor with prolonged duration of action b